Checking for lymph node spread and tumor deposits in the posterior gastric mesentery after distal stomach cancer surgery
Official title: Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery Following D2 Lymphadenectomy Plus Complete Mesogastric Excision in Patients Who Received Distal Gastrectomy: A Prospective Observational Study
Run by First Affiliated Hospital of Zhejiang University · NCT06736847 · Data updated 2026-11-12
This project will check if adults having distal stomach cancer surgery (distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision) have lymph node metastases or tumor deposits in the posterior gastric mesentery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | May 1, 2024 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | September 2, 2025 |
| Trial ID | NCT06736847 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 to 84 with primary distal gastric adenocarcinoma staged cT2-4N0-3M0 who undergo distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision and meet ASA I–III and other study criteria are ideal candidates.
✕Probably not a fit
Patients with very advanced or metastatic disease (cT4b/M1), prior neoadjuvant therapy, BMI over 30, prior upper abdominal surgery, total or proximal gastrectomy, or concurrent other malignancies are unlikely to benefit from the protocol findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study of patients who undergo distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision for gastric adenocarcinoma. Surgeons will resect the posterior gastric mesentery during the procedure and pathologists will examine the tissue for metastatic lymph nodes (including No.11p and part of No.11d) and tumor deposits. The number and distribution of positive nodes and any tumor deposits will be recorded and correlated with preoperative staging and clinical features. The study is single-center, conducted at the First Affiliated Hospital, Zhejiang University School of Medicine, and enrolls patients meeting defined inclusion and exclusion criteria.
Why it matters
Potential benefit: If successful, the findings could improve surgical planning and pathological staging by clarifying how often the posterior gastric mesentery harbors metastatic nodes or tumor deposits, potentially reducing recurrence from missed disease.
How similar studies have gone: Previous work, including the DCGC01 findings, suggests D2 plus CME removes more lymph nodes and may improve long-term outcomes, but detailed mapping of metastasis specifically in the posterior gastric mesentery remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged older than 18 years and younger than 85 years 2. Primary gastric adenocarcinoma confirmed by preoperative pathology result 3. cT2-4N0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 7th Edition 4. Patients who received distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision 5. American Society of Anesthesiologists (ASA) class I, II, or III 6. Written informed consent Exclusion Criteria: 1. Negative preoperative biopsy 2. Too late tumour stage or metastasis (cT4b/M1) 3. BMI\>30 kg/m2 4. Total gastrectomy or proximal gastrectomy 5. previous neoadjuvant chemotherapy or radiotherapy 6. Previous upper abdominal surgery 7. Combined with other malignant diseases 8. Reject operation
Where it's running
-
Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Tao Wang, Ph.d
- Email: 15002740874@163.com
- Phone: +86-197-068-25286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Microplastic exposure and progression of stomach precancerous changes
This project will test if adults with higher microplastic exposure are more likely to have precancerous stomach changes or gastric cancer.
-
Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma
This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.
-
Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays
This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.
-
Examining metastatic lymph nodes in each part of the stomach's mesentery during gastrectomy
This project will see if the number and location of metastatic lymph nodes across the six stomach mesenteries predict outcomes for adults undergoing D2 plus complete mesogastric excision for gastric cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.